BioCardia Q2 2026: Cash Runway Extended to 2027, Japan Submission on Track
BCDA sits 20% above its 52-week low of $0.75 on light trading volume (0.1× avg).
Summary
BioCardia reported Q2 2026 financial results with a narrower net loss and $4.1 million in cash, providing runway into 2027. The company also highlighted positive regulatory progress in Japan and the U.S. for its CardiAMP cell therapy.
Key Events · Earnings and Guidance · BCDA
-
Q2 2026 Financial Results
Net loss narrowed to $1.6 million from $2.0 million in Q2 2025. Cash and cash equivalents totaled $4.1 million as of June 30, 2026, providing anticipated runway into 2027.
-
Regulatory Progress in Japan and U.S.
Japan's PMDA supports a Shonin pre-market submission for CardiAMP Cell Therapy in ischemic HFrEF, planned for Q4 2026. FDA confirmed the ongoing CardiAMP HF II trial may support PMA approval.
-
Clinical Trial Updates
CardiAMP HF II trial is actively enrolling with four sites. CardiAMP CMI cohort results presented at EuroPCR showed improved exercise tolerance and reduced angina episodes.
-
Upcoming Milestones
Shonin submission to Japan PMDA expected in Q4 2026. Strategic partnership and licensing discussions ongoing for Helix/Heart3D delivery platform and allogeneic MSC platform.
Analysis · BCDA · Life Sciences
The Q2 2026 results show a reduced net loss and a cash position of $4.1 million, extending runway into 2027. Positive regulatory updates include PMDA support for a Shonin submission in Japan and FDA confirmation that the CardiAMP HF II trial may support PMA. For a micro-cap company with a recent history of financial distress, these developments are material: they reduce near-term liquidity risk and advance key regulatory milestones.
At the time of this filing, BCDA was trading at $0.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.1M. The 52-week trading range was $0.75 to $2.29. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.